51 related articles for article (PubMed ID: 29288944)
21. Synthesis, characterization and biological evaluation of anti-cancer indolizine derivatives via inhibiting β-catenin activity and activating p53.
Moon SH; Jung Y; Kim SH; Kim I
Bioorg Med Chem Lett; 2016 Jan; 26(1):110-3. PubMed ID: 26608553
[TBL] [Abstract][Full Text] [Related]
22. Novel 1-(7-ethoxy-1-benzofuran-2-yl) substituted chalcone derivatives: Synthesis, characterization and anticancer activity.
Coskun D; Erkisa M; Ulukaya E; Coskun MF; Ari F
Eur J Med Chem; 2017 Aug; 136():212-222. PubMed ID: 28494257
[TBL] [Abstract][Full Text] [Related]
23. Studies on indolizines. Evaluation of their biological properties as microtubule-interacting agents and as melanoma targeting compounds.
Ghinet A; Abuhaie CM; Gautret P; Rigo B; Dubois J; Farce A; Belei D; Bîcu E
Eur J Med Chem; 2015 Jan; 89():115-27. PubMed ID: 25462232
[TBL] [Abstract][Full Text] [Related]
24. Discovery of indolizines containing triazine moiety as new leads for the development of antitumoral agents targeting mitotic events.
Lucescu L; Ghinet A; Belei D; Rigo B; Dubois J; Bîcu E
Bioorg Med Chem Lett; 2015 Sep; 25(18):3975-9. PubMed ID: 26227778
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis, and evaluation of chalcone analogues incorporate α,β-Unsaturated ketone functionality as anti-lung cancer agents via evoking ROS to induce pyroptosis.
Zhu M; Wang J; Xie J; Chen L; Wei X; Jiang X; Bao M; Qiu Y; Chen Q; Li W; Jiang C; Zhou X; Jiang L; Qiu P; Wu J
Eur J Med Chem; 2018 Sep; 157():1395-1405. PubMed ID: 30196062
[TBL] [Abstract][Full Text] [Related]
26. Biological evaluation of indolizine-chalcone hybrids as new anticancer agents.
Park S; Kim EH; Kim J; Kim SH; Kim I
Eur J Med Chem; 2018 Jan; 144():435-443. PubMed ID: 29288944
[TBL] [Abstract][Full Text] [Related]
27. Current scenario of chalcone hybrids with antibreast cancer therapeutic applications.
Wang H; Zhu J; Zhang Q; Tang J; Huang X
Arch Pharm (Weinheim); 2024 May; 357(5):e2300640. PubMed ID: 38227398
[TBL] [Abstract][Full Text] [Related]
28. A Review: Discovering 1,3,4-oxadiazole and Chalcone Nucleus for Cytotoxicity / EGFR Inhibitory Anticancer Activity.
Patil S; Bhandari S
Mini Rev Med Chem; 2022; 22(5):805-820. PubMed ID: 34477516
[TBL] [Abstract][Full Text] [Related]
29. 1,3,5-Triazine-azole Hybrids and their Anticancer Activity.
Guo H; Diao QP
Curr Top Med Chem; 2020; 20(16):1481-1492. PubMed ID: 32156236
[TBL] [Abstract][Full Text] [Related]
30. Chalcone hybrids as potential anticancer agents: Current development, mechanism of action, and structure-activity relationship.
Gao F; Huang G; Xiao J
Med Res Rev; 2020 Sep; 40(5):2049-2084. PubMed ID: 32525247
[TBL] [Abstract][Full Text] [Related]
31. Inhibitory activities of indolizine derivatives: a patent review.
Dawood KM; Abbas AA
Expert Opin Ther Pat; 2020 Sep; 30(9):695-714. PubMed ID: 32684068
[TBL] [Abstract][Full Text] [Related]
32. Tetrazole hybrids with potential anticancer activity.
Zhang J; Wang S; Ba Y; Xu Z
Eur J Med Chem; 2019 Sep; 178():341-351. PubMed ID: 31200236
[TBL] [Abstract][Full Text] [Related]
33. Recent Advances in Phenanthroindolizidine and Phenanthroquinolizidine Derivatives with Anticancer Activities.
de Fatima Pereira M; Rochais C; Dallemagne P
Anticancer Agents Med Chem; 2015; 15(9):1080-91. PubMed ID: 25991426
[TBL] [Abstract][Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
